Penn study finds mutation driving deadlier brain tumors and potential therapy to stop it
(University of Pennsylvania School of Medicine) A poorly understood mutation in the brain cancer glioblastoma (GBM) is now being implicated for the first time as the driver of rare but deadlier cases of the disease.
Publication date: Available online 16 November 2018Source: Biosensors and BioelectronicsAuthor(s): Jessica L. Scoggin, Chao Tan, Nam H. Nguyen, Urna Kansakar, Mahboubeh Madadi, Shabnam Siddiqui, Prabhu U. Arumugam, Mark A. DeCoster, Teresa A. MurrayAbstractGlutamate, a major excitatory neurotransmitter in the central nervous system, is essential for regulation of thought, movement, memory, and other higher functions controlled by the brain. Dysregulation of glutamate signaling is associated with severe neuropathological conditions, such as epilepsy, and glioma, a form of brain cancer. Glutamate signals are currently detect...
MicroRNA‑940 promotes cell proliferation and invasion of glioma by directly targeting Kruppel‑like factor 9. Mol Med Rep. 2018 Nov 07;: Authors: Zhang D, Hao P, Jin L, Wang Y, Yan Z, Wu S Abstract MicroRNA‑940 (miR‑940) has been extensively studied in the pathogenesis of numerous types of human cancer; however, the expression pattern, roles and molecular mechanisms underlying the regulatory actions of miR‑940 in glioma remain unknown. The present study aimed to further investigate miR‑940 by studying its expression, roles and mechanisms of action in glioma. Reverse transcription‑quan...
In this article, we review the role of temozolomide in the management of patients with primary brain tumors, brain metastases, leptomeningeal carcinomatosis, and other selected CNS cancers.
CANCER: Brain tumours can be deadly, but many people don ’t notice they have one for a long period of time, by which point it may be to late to treat it. These are five early symptoms of a brain tumour you must be aware of.
This study aimed to investigate the role of S100B in NSCLC brain metastasis. The results showed that serum S100B correlated significantly with NSCLC brain metastasis (P
m Cherkasov Orphan nuclear receptor TLX (NR2E1) plays a critical role in the regulation of neural stem cells (NSC) as well as in the development of NSC-derived brain tumors. In the last years, new data have emerged implicating TLX in prostate and breast cancer. Therefore, inhibitors of TLX transcriptional activity may have a significant impact on the treatment of several critical malignancies. However, the TLX protein possesses a non-canonical ligand-binding domain (LBD), which lacks a ligand-binding pocket (conventionally targeted in case of nuclear receptors) that complicates the development of small molecule inhibit...
ConclusionsSignificant associations were found between PROMIS and SDS as well as clinical and demographic characteristics. Brief ‐yet‐precise PROMIS CATs can be used to systematically assess symptom burden experienced by children with brain tumors.
(Worcester Polytechnic Institute) Researchers at Worcester Polytechnic Institute and Albany Medical College, along with corporate partners GE Global Research and Acoustic MedSystems, have received a five-year, $3.5 million award from the National Institutes of Health through the National Cancer Institutes' Academic-Industrial Partnership program, to continue development of an innovative robotic system that, operating within an MRI scanner, can deliver a minimally invasive probe into the brain to destroy metastatic brain tumors with high-intensity therapeutic ultrasound under real-time guidance.
(University of California - San Francisco) In a new study published Nov. 13 in the journal eLife, UC San Francisco scientists report the first animal model of glioma -- the most aggressive and most common form of brain cancer in the US -- that can also be used to study the long-term effects of radiation therapy in tumor-bearing brains. Using this mouse model, the researchers showed that a drug that temporarily suppresses a key component of the brain's immune system can prevent radiation-associated cognitive decline.
ConclusionsThe results indicate that 6-MOMIPP is a novel microtubule disruptor that targets the colchicine binding site on β-tubulin to induce mitotic arrest and cell death. The ability of 6-MOMIPP to penetrate the blood–brain barrier and inhibit growth of glioblastoma xenografts suggests that it warrants further preclinical evaluation as poten tial small-molecule therapeutic that may have advantages in treating primary and metastatic brain tumors.